safinamide has been researched along with Dyskinesia, Drug-Induced in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brugnoli, A; Caccia, C; Gardoni, F; Keywood, C; Kulisevsky, J; Mellone, M; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Sosti, V; Vailati, S | 1 |
| Di Paolo, T; Grégoire, L; Jourdain, VA; Roach, A; Townsend, M | 1 |
| Anand, R; Bhatt, MH; Borgohain, R; Chirilineau, D; Forrest, E; Giuliani, R; Lucini, V; Meshram, C; Rice, P; Stanzione, P; Stocchi, F; Szasz, J | 1 |
| Deeks, ED | 1 |
2 review(s) available for safinamide and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
▼ Safinamide for Parkinson's disease.
Topics: Alanine; Benzylamines; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease | 2018 |
Safinamide: first global approval.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Cognition Disorders; Drug Approval; Dyskinesia, Drug-Induced; Humans; Internationality; Parkinson Disease | 2015 |
1 trial(s) available for safinamide and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
Topics: Aged; Alanine; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; International Cooperation; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Treatment Outcome | 2014 |
2 other study(ies) available for safinamide and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Safinamide Modulates Striatal Glutamatergic Signaling in a Rat Model of Levodopa-Induced Dyskinesia.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Excitatory Amino Acid Agents; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Signal Transduction | 2018 |
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Treatment Outcome | 2013 |